AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019An assay to measure drug tolerance of M. tuberculosis in the caseous center of pulmonary lesionsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Levofloxacin target attainment analysis in MDR-TB patients: time is ripe for proactive TDMView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment AnalysisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019PK-PD of isoniazid given at different doses among patients with MDR-TB with INH resistance mediated by inhA mutations: modeling results from ACTG A5312.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Can longitudinal PKPD biomarkers be used to forecast treatment outcome instead of M2 conversion? A population pharmacokinetic-pharmacodynamic analysis in drug sensitive pulmonary tuberculosis.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The OptiRIF study: pharmacokinetics of high-dose rifampicin in childrenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Exposures to first-line drugs in African and Indian children with drug-susceptible tuberculosis using novel fixed-dose-combination tablets at WHO dosing recommendation in the SHINE trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Ethionamide population pharmacokinetic model and Monte Carlo Simulation in patients with multidrug-resistant tuberculosisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Increased bactericidal activity but dose-limiting tolerability at 50 mg/kg rifampicinView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacogenetics and pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Co-administration of pretomanid with rifampin or rifabutin among patients with pulmonary TB: interim PK results from “Assessing Pretomanid for Tuberculosis” (APT) trialView Abstract
